PROWLER

K972037 · The Buzzz Corp. · INI · Jul 3, 1997 · Physical Medicine

Device Facts

• Record ID: K972037
• Device Name: PROWLER
• Applicant: The Buzzz Corp.
• Product Code: INI · Physical Medicine
• Decision Date: Jul 3, 1997
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 890.3800
• Device Class: Class 2

Indications for Use

To offer to the consuming public, an electric 3-wheel scooter, that is reliable, safe and affordable.

Device Story

The ADI 3-wheel scooter is an electric mobility device designed for use by the general public. It functions as a personal transport vehicle, providing mobility assistance. The device is operated by the user. It is intended to provide a reliable, safe, and affordable means of transportation for individuals requiring mobility support.

Clinical Evidence

No clinical data provided; bench testing only.

Technological Characteristics

Electric 3-wheel scooter; battery-powered motor; mechanical steering and braking components.

Indications for Use

Indicated for the general consuming public as an electric 3-wheel scooter for personal mobility.

Regulatory Classification

Identification

A motorized three-wheeled vehicle is a gasoline-fueled or battery-powered device intended for medical purposes that is used for outside transportation by disabled persons.

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo is circular with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the circle is a stylized image of three human profiles facing right, with flowing lines connecting them.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

K972037

Mr. Ken Casev ·President American Dream International Corporation 213 East Luzerne Avenue Larksville, Pennsylvania 18704

JUL - 3 :097

Re: K972036 Stealth 8972032 Prowler K972038 Intruder Requlatory Class: II Product Code: INI Dated: June 2, 1997 Received: June 2, 1997

Dear Mr. Casey:

We have reviewed your Section 510(k) notification of intent to market the devices referenced above and we have determined these devices are substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the devices, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your devices are classified (see above) into either class II (Special Controls) or class III (Premarket Approval), they may be subject to such additional controls. Existing major regulations affecting your devices can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General ene oooa handhondring fracesse in and that, through periodically - -----GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your devices in Please note: this response to your the Federal Reqister.

{1}------------------------------------------------

## Page 2 - Mr. Ken Casey

premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your devices as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your devices to legally marketed predicate devices results in a classification for your devices and thus, permits your devices to proceed to the market.

If you desire specific advice for your devices on our labeling requlation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your devices, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number [phone] or [phone] or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

Mark N Milbers

Celia M. Witten, Ph.D., M.D. Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosures

{2}------------------------------------------------

Page 1 of 1

510(k) Number (if known):

ADI 3-wheel scooter Device Name:___

Indication For Use:

To offer to the consuming public, an electric 3-wheel scooter, that is reliable, safe and affordable.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

OR

(Division Sign-Off)
Division of General Restorative Devices

| 510(k) Number | ________________________________________________________________________________________________________________________________________________________________ |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Prescription Use (Per 21 CFR 801.109 Over-The-Counter Use